‘The future is challenging us to innovate our delivery methods’: PRA

By Melissa Fassbender

- Last updated on GMT

(Image: Frank Lombardi Jr)
(Image: Frank Lombardi Jr)

Related tags Asia Japan Pra health sciences

Biopharmaceutical companies are increasingly relying on CROs in Japan, says an executive with PRA, which recently established a new subsidiary in the country.

“The benefits of operating in Japan certainly outweigh the challenges,”​ said Atsushi Ogawa, president, PRA Japan.

Additionally, the reliance on contract research organizations (CROs) is increasing in Japan, he said, and sponsors have a need for research and development partners. This is due in part to the globalization of the industry, with an increasing number of studies in Japan being multi-national in nature.

Read more:Japan v. China: Becoming two of the largest pharma markets in the world

“Another key benefit of operating in Japan is that we can bring in talented, experienced staff members with valuable expertise in the market,” ​said Ogawa, adding that the country has a motivated workforce who wants to grow and innovate.

In line with this, PRA has offices in the Kansai area, including Osaka, Kyoto, Kobe, and Nara, which Ogawa said are ideal locations for a CRO due to the proximity to pharmaceutical companies, universities, hospitals, and research laboratories.

“The Kansai area also attracts great talent because the commute time is short, land prices are lower, and the transportation network is in place,”​ he added. “The area is a wonderful place to maintain work-life balance.”

Still, the market is challenged by the combination of “high people costs and processes being largely relationship-based,”​ said Ogawa, adding that this means cost per patient is high with any provider.

However, PRA is looking forward, he said, and aims to make Japan a more cost-effective global country to select for trials and Japan-only studies more effective.

“The pharmaceutical R&D landscape is changing, and the future is challenging us to innovate our delivery methods. PRA is leveraging its corporate investments in data and technology to benefit the Japanese market,” ​added Samir Shah, executive vice president and president, strategic solutions at PRA Health Science.

Among the company’s scalable, proprietary solutions moving into the Japanese market are Clinical 6, Symphony, Prism, and Predictivv, Shah told us.

Additionally, PRA late last month announced​ that it has bought out its joint venture with Takeda, thus establishing a new subsidiary based in Japan: PRA Health Sciences K.K.

The addition of Takeda’s staff increases PRA’s totals employee numbers to 450 in Japan, with the opportunity for near term growth – which is occurring rapidly in the country, said Shah.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more